替吉奥胶囊联合多西紫杉醇每 2 周方案作为老年晚期胃癌患者一线治疗的研究

Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer.

机构信息

Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.

出版信息

Anticancer Res. 2013 Feb;33(2):697-704.

PMID:23393370

Abstract

BACKGROUND/AIM: This study assessed the toxicity and activity of biweekly docetaxel and S-1 combination therapy in elderly patients with advanced gastric cancer.

PATIENTS AND METHODS

One-hundred and thirteen patients were enrolled: 35 were 75 years old or more. The objective response rate, toxicity, progression-free survival (PFS), and overall survival (OS) were compared.

RESULTS

Dose reduction was significantly frequent in the elderly group (24/35 versus 25/78, p<0.001). The overall response rate was 54.9%. Out of these, 18 (15.9%) underwent gastrectomy (13 R0 gastrectomy). The median OS was 17.3 months and the median PFS was 8.0 months. Neutropenia was the most frequently observed hematological toxicity at grade 3 and 4 (34.5%), followed by leukopenia (24.8%). Most non-hematological toxicities were of grade 1 or 2. There were no significant differences in overall response rate, median OS, median PFS, or toxicities between the two groups.

CONCLUSION

This combination offers favourable survival benefits with controllable tolerance for therapy of AGC in the elderly.

摘要

背景/目的：本研究评估了每周两次多西他赛和 S-1 联合治疗在老年晚期胃癌患者中的毒性和疗效。

患者和方法

共纳入 113 例患者：35 例患者年龄在 75 岁及以上。比较了客观缓解率、毒性、无进展生存期（PFS）和总生存期（OS）。

结果

老年组剂量减少的频率明显较高（24/35 例与 25/78 例，p<0.001）。总缓解率为 54.9%。其中，18 例（15.9%）进行了胃切除术（13 例 RO 胃切除术）。中位 OS 为 17.3 个月，中位 PFS 为 8.0 个月。中性粒细胞减少是最常见的 3 级和 4 级血液学毒性（34.5%），其次是白细胞减少（24.8%）。大多数非血液学毒性为 1 级或 2 级。两组之间的总缓解率、中位 OS、中位 PFS 或毒性均无显著差异。